Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON® for the Treatment of Persistent Corneal Epithelial Defect (PCED)
January 09, 2023 07:31 ET
|
Amber Ophthalmics, Inc.
SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Amber Ophthalmics, Inc. (Amber), a privately held clinical-stage biopharmaceutical company focused on developing innovative therapies for rare ophthalmic...